Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted For Relutrigine In Dravet Syndrome; Praxis Plans To Initiate An All-DEE Trial (EMERALD), Inclusive Of Dravet Syndrome, In 1H2025

BenzingaDec 18 08:14 ET

Express News | Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

ReutersDec 18 08:00 ET

9 Health Care Stocks With Whale Alerts In Today's Session

BenzingaDec 16 12:35 ET

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Simply Wall StDec 13 06:50 ET

H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $120

Moomoo NewsDec 12 06:31 ET · Ratings

Praxis Precision Med Price Target Maintained With a $120.00/Share by HC Wainwright & Co.

Dow JonesDec 12 06:28 ET · Ratings